Less than 3% of infertile couples worldwide receive treatment and only 1% have a child through in vitro fertilization (IVF). 

So the industry’s capacity remains limited, which for INVO Bioscience creates challenges for providing access to care for the volume of patients who need it. 

A survey conducted by “Resolve: The National Infertility Association” indicates that the top two reasons couples do not use IVF are cost and geographic availability (and/or capacity).

While there have been large increases in the use of IVF, approximately 2.6 million cycles of assisted reproductive technology (ART), including IVF, intrauterine insemination (IUI) and other fertility treatments, are still performed worldwide each year, producing about 500,000 babies. 

Infertile couples

The global ART market is a large, multi-billion dollar industry, growing at a strong pace in many parts of the world as rising infertility rates, increased patient awareness, acceptance of treatment options and improved financial incentives, such as insurance and government assistance, continue to drive demand. 

According to China Insights Consultancy (CIC), as of December 31, 2022, there were more than 213 million infertile couples in the Asia-Pacific region. 

While there have been substantial increases in the use of ART, according to CIC, only approximately 1.47 million ART cycles, including IVF and other fertility treatments, were performed in Asia Pacific in 2022. 

This equates to less than 1.1% of infertile couples in Asia Pacific receiving treatment and only 0.7% having a child through ART in 2022.

Fertility problems

In the United States, infertility affects approximately 10%-15% of couples of childbearing age, according to the American Society for Reproductive Medicine (2017). 

According to the Centers for Disease Control (CDC), there are approximately 6.7 million women with fertility problems in the United States. 

According to 2021 data from the CDC’s National ART Surveillance System, approximately 413,000 IVF cycles were performed at 453 IVF centers, leaving the United States with a large, underserved patient population similar to most markets worldwide.